Valneva Se ADR VALN

$5.63 +0.07 (1.26%)

Valuation

Market cap
562,674,000
Revenue TTM
$197,610,000
Net income TTM
$-130,330,000
PE ratio
0.00
Forward PE
—
Profit margin
-65.95%
Debt to equity
2.27

Trading

Volume
11,459
Avg volume
92,530
Day's range
$5.62 – $5.73
Shares out
94,886,000
Stochastic %K
2%
Beta
1.53
Analysts
Strong Sell
Price target
$12.20

Price

Company profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing entero...

Show more

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.

Industry
Biotechnology
Sector
Healthcare
Phone
33 2 28 07 37 10
Website
https://valneva.com
Address
6 rue Alain Bombard, Saint-Herblain, France

Latest news

Stocktwits

Skywulf Oct 13, 10:43 PM
$VALN unfortunately with no supports now and constant negative news, likely to see this float into the 4s or even lower depending how long of a wait on some good news. Good sell and re-entry setup for now.
0 replies
tt01 Oct 10, 6:55 AM
$VALN It will go to 3-4$ 🥹🥹🥹
0 replies
Skywulf Oct 10, 12:28 AM
$VALN RIP - Shigella Vaccine Results Pushed to Q4 2026 Valneva’s newly published October 2026 investor presentation contains a notable change to its clinical development timeline. The company now expects results from both studies of its S4V2 Shigella vaccine candidate in Q4 2026 (October–December), rather than Q3 2026 as previously projected. This affects: * Phase 2b human challenge trial: Preliminary vaccine efficacy. * Phase 2 infant trial: Safety and immune response. Valneva had previously expected both results by September 30. The company has not disclosed a reason for the revised timing or announced negative clinical findings. Impact: Mildly negative for near-term catalyst timing, but not necessarily for the vaccine’s prospects. Shigella remains an important secondary pipeline opportunity.
0 replies
Skywulf Oct 8, 2:13 PM
$VALN going to be a rough close this week unless magically some other news appears :/
0 replies
Jaymuss Oct 8, 1:47 PM
$VALN It's called investing, don't let the moneee hungary daygamblers scare you out of your positions. It may be a quarter or more too soon to anticipate the Lyme disease vaccine, and approval for that is not guaranteed, but there's nothing else on the market for that terrible affliction.
1 replies
OpenOutcrier Oct 8, 12:55 PM
$VALN (-4.6% pre) Valneva ADRs fall as UK revokes IXCHIQ marketing authorization https://ooc.bz/l/116949
0 replies
briefingcom Oct 8, 12:51 PM
$VALN: Valneva plunges after UK regulators revoke IXCHIQ’s marketing authorization after a benefit-risk review of prior safety data.
0 replies
Facade78 Oct 8, 12:04 PM
$VALN They also delayed lime vaccine trial readout to 2027..
1 replies